Guardant Health has announced a multi-year global strategic collaboration with Merck (known as MSD outside the US and Canada) to support the development and commercialization of Merck’s oncology pipeline using Guardant’s Infinity™ Smart platform.
Under the agreement, Guardant’s liquid and tissue biopsy portfolio will be used as clinical trial enrollment assays across Merck’s global oncology studies. The collaboration also includes joint efforts to develop companion diagnostics to support regulatory approvals and to co-commercialize